Fennec Pharmaceuticals Inc (FENC)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Fennec Pharmaceuticals Inc, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Fennec Pharmaceuticals Inc (FENC) has returned -20.13% so far this year and 0.99% over the past 12 months. Looking at the last ten years, FENC has achieved an annualized return of 12.95%, outperforming the S&P 500 Index benchmark, which averaged 12.16% per year.

Based on dividend-adjusted daily data since Sep 9, 2014, FENC's average daily return is +0.21%, while the average monthly return is +1.83%. At this rate, your investment would double in approximately 3.2 years.

Historically, 52% of months were positive and 48% were negative. The best month was Jun 2017 with a return of +69.3%, while the worst month was Nov 2021 at -52.6%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 5 months.

On a daily basis, FENC closed higher 44% of trading days. The best single day was Nov 30, 2015 with a return of +328.5%, while the worst single day was Nov 27, 2015 at -78.1%.

Fennec Pharmaceuticals Inc has an annualized alpha of 56.16%, beta of 0.64, and R² of 0.01 versus S&P 500 Index. Calculated based on daily prices since September 10, 2014.

• This stock participated in 59.30% of S&P 500 Index downside but only 50.70% of its upside — more exposed to losses than it benefited from rallies.
• Beta of 0.64 may look defensive, but with R² of 0.01 this stock is largely uncorrelated with S&P 500 Index — low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R² of 0.01 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

FENC ranks 38 for risk / return — below 38% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.

The table below present risk-adjusted performance metrics for Fennec Pharmaceuticals Inc (FENC) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Fennec Pharmaceuticals Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Fennec Pharmaceuticals Inc was 91.43%, occurring on Nov 27, 2015. Recovery took 338 trading sessions.

The current Fennec Pharmaceuticals Inc drawdown is 57.08%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Fennec Pharmaceuticals Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Fennec Pharmaceuticals Inc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.